Canada: Health Canada And Federal Court Make Important Biologic Decisions

Last Updated: January 21 2014
Article by Urszula Wojtyra

Last week was a landmark for biologics in Canada: Health Canada approved two antibody subsequent entry biologics (SEBs) and the Federal Court issued a decision finding a patent directed at a therapeutic use of an antibody to be valid and infringed.

Health Canada approves first antibody SEBs

On January 15, 2014, Health Canada issued notices of compliance (NOCs) to Celltrion Healthcare Co. Ltd. for REMSIMA and INFLECTRA, which both contain a monoclonal antibody, infliximab, as the medicinal ingredient. Janssen Inc. markets REMICADE, containing infliximab, for a number of indications, including rheumatoid arthritis, Crohn's disease, ulcerative colitis and psoriasis. It is not clear at this time for which indications REMSIMA and INFLECTRA were approved.

Both INFLECTRA and REMSIMA were granted marketing approval in the European Union in September 2013. The approvals were granted to Celltrion Healthcare Hungary Kft. (INFLECTRA) and Hospira UK Limited (REMSIMA). Both were approved as "biosimilars" to REMICADE, and have been approved in all the same therapeutic areas as REMICADE.

These approvals bring the total number of SEBs approved in Canada to date to three, including Sandoz's OMNITROPE, which contains somatotropin.

Federal Court issues decision in biologic patent infringement action: patent valid and infringed

On January 17, 2014, Justice Hughes of the Federal Court rendered a decision in a biologic patent infringement action, finding AbbVie Corporation (Abbvie)'s patent valid and infringed by Janssen Inc. (Janssen)'s antibody drug STELARA (ustekinumab) used in the treatment of psoriasis: AbbVie Corporation v Janssen Inc, 2014 FC 55. AbbVie does not market and does not have an NOC for a drug containing ustekinumab for treatment of psoriasis.

The patent at issue:

AbbVie, formerly Abbott, owns the patent at issue, Canadian Patent No. 2,365,281, titled "Human Antibodies that Bind Human IL-12 and Methods for Producing."

The patent relates to isolated human antibodies that bind IL-12, one of many cytokines that function to mediate and regulate immune reactions in the body. The binding of the antibody to IL-12 prevents receptor binding, thereby making the antibody useful in the treatment of diseases, including psoriasis. The patent describes the use of a particular method, phage display, to make monoclonal antibodies.

Example 9 contained the sole clinical data in the patent, describing a double-blind clinical trial of the administration of a particular antibody, J695, or placebo to healthy subjects. One of the subjects was suffering from psoriasis at the beginning of the study, happened to receive the antibody treatment, and reported an improvement in his psoriasis symptoms.

Claim construction:

Of the 226 claims in the patent, only two were at issue in the case. Justice Hughes construed the two claims as being directed to the use of an isolated human antibody, however created, that binds IL-12 with a minimum specified affinity and has a minimum specified potency in particular in vitro assays as set out in the claims, for the treatment of psoriasis.

Infringement:

The medicinal ingredient in Janssen's STELARA product is a human antibody derived using transgenic mouse technology, as opposed to phage display used to derive J695, the antibody described in the patent. However, given the construction that the claims were not limited to human antibodies created by a particular method, this was found insufficient to take STELARA outside the scope of the claims. Furthermore, AbbVie had conducted testing of the STELARA antibody, which the Court accepted as establishing that the antibody met the affinity and potency required by the claims. As such, Justice Hughes found that STELARA infringed the claims.

Invalidity:

Janssen submitted that the patent was invalid on the basis of, inter alia, obviousness and overbreadth.

Obviousness. Justice Hughes emphasized that that the claims are the appropriate focus for identifying the inventive concept of the claims at issue, as opposed to "some generalized concept of invention as expressed in the patent as a whole." For the claims at issue, he held the inventive concept was that "psoriasis may be treated by the use of human antibodies that bind to human IL-12, which antibodies have a stickiness of at least the claimed amount and a potency of at least the claimed amount." The difference between the prior art and the invention as claimed "is that between hope and certainty." He explained, at paragraph 133:

...before the invention was made, there was a hope that, among the "soup" of cytokines in the human body, if an [antibody] was found to bind to one or more of them, then certain human diseases might be treatable. The invention here was that it was found that a particular cytokine should be bound by an [antibody] having certain properties, and then psoriasis would be treatable. [Emphases in original]

Distinguishing between the "worth a try" approach and the "more or less self-evident" approach, holding the latter to be the law in Canada, he found that AbbVie's researchers "got lucky," and that the invention was not self-evident having regard to the prior art.

Overbreadth. Justice Hughes framed the question as follows:

[148]...Having claimed the invention without reference to the specific antibody described in the patent, or even the specific method by which it was described to be made in the patent, can the claim be so broad as to cover whatever antibody falls within the constraints as [construed above] and still be valid?

On the particular facts of this case and in light of the evidence, the answer was yes.

The evidence showed that techniques used to create antibodies were well known, as were the methods for measuring affinity and potency. Furthermore, there was no evidence that there was anything falling within the scope of the asserted claims that was not useful for the treatment of psoriasis, or that a skilled person could not have created an antibody that met the parameters of the two asserted claims. Justice Hughes found that the claims were not merely functionally claiming a desired result, particularly given the fact that it was AbbVie who first confirmed that if an antibody did bind to IL-12, psoriasis could be treated. Before this confirmation, there was only a hope or speculation. Furthermore, the claims included certain criteria for the antibody, namely specified minimum affinity and potency:

[167]...AbbVie was the first to confirm that, if you want to treat psoriasis, you must get an antibody that binds to IL-12 and it must have at least a certain level of stickiness and potency. That is very different from saying - we have a particular antibody (J695), and we put it into people, and it treats their psoriasis; therefore, we want a patent claiming any antibody that does that. There may be many ways to treat psoriasis, but AbbVie's way is to have an antibody that does so by binding to IL-12 with at least a certain level of stickiness and potency.

Justice Hughes concluded that "there is no simple principle that can be universally applied that would say, for example, that you have shown only one or two antibodies in your disclosure; you cannot claim all that will do the particular trick you have in mind."

Remedy. Justice Hughes declared, as between the parties, the claims valid and infringed. Pursuant to a bifurcation order, the trial dealt only with infringement and invalidity. Issues relating to remedy, including entitlement to an injunction, and quantum, were deferred to a subsequent trial.

Janssen may appeal to the Federal Court of Appeal, as of right.

For further information, please contact a member of our firm's Pharmaceutical Litigation team.

The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Urszula Wojtyra
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions